Details of the Drug Formulation (DFM)
General Information of DFM (ID: F12033) | |||||
---|---|---|---|---|---|
Name |
Linaclotide 0.29 mg capsule
|
||||
Company |
Allergan
|
||||
Active Pharmaceutical Ingredient (API) | Linaclotide | API Info click to show the detail info of this API | |||
Irritable bowel syndrome | ICD-11: DD91 | Approved | |||
Drug Inactive Ingredient (DIGs) | |||||
DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
E0N0NF | DIG Info | Calcium chloride | Antimicrobial preservative ... | ||
E07QDG | DIG Info | Leucine | Antiadherent ... | ||
E05BSD | DIG Info | Titanium dioxide | Coating agent ... | ||
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
---|---|---|---|---|---|---|
Potential-driven transporter (PDT) | ||||||
DBT Name: Integral membrane E16 (SLC7A5) | Click to Show/Hide | |||||
Detailed Information | DBT Info click to show the detail info of this DBT | |||||
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
Interacting DIG | Leucine | |||||
Biological Activity | IC50 = 85000 nM (tested by experiment) | [1] | ||||
Tested Species | Homo sapiens (Human) | |||||
UniProt ID | LAT1_HUMAN | |||||
References | |||||
---|---|---|---|---|---|
1 | Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). J Med Chem. 2018 Aug 23; 61(16):7358-7373. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.